Amirali Talasaz Sells 37,500 Shares of Guardant Health (NASDAQ:GH) Stock

Guardant Health, Inc. (NASDAQ:GH) CEO Amirali Talasaz sold 37,500 shares of the business’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $169.16, for a total value of $6,343,500.00. Following the completion of the transaction, the chief executive officer directly owned 37,500 shares of the company’s stock, valued at approximately $6,343,500. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Amirali Talasaz also recently made the following trade(s):

• On Friday, June 26th, Amirali Talasaz sold 116,972 shares of Guardant Health stock. The shares were sold at an average price of $150.79, for a total value of $17,638,207.88.
• On Monday, June 29th, Amirali Talasaz sold 143,028 shares of Guardant Health stock. The shares were sold at an average price of $151.54, for a total value of $21,674,463.12.

Guardant Health Trading Up 1.1%

Shares of GH stock opened at $164.92 on Wednesday. The firm has a 50-day moving average price of $155.33 and a 200 day moving average price of $119.49. Guardant Health, Inc. has a twelve month low of $53.40 and a twelve month high of $176.58. The company has a market capitalization of $22.13 billion, a price-to-earnings ratio of -47.25 and a beta of 1.60.

Guardant Health (NASDAQ:GH) last released its earnings results on Thursday, July 30th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.34. The firm had revenue of $334.98 million during the quarter, compared to analysts’ expectations of $314.23 million. During the same quarter last year, the company posted ($0.44) earnings per share. Guardant Health’s revenue for the quarter was up 44.3% on a year-over-year basis. As a group, research analysts predict that Guardant Health, Inc. will post -2.98 earnings per share for the current year.

Institutional Investors Weigh In On Guardant Health

A number of institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC raised its stake in Guardant Health by 14.5% during the second quarter. GAMMA Investing LLC now owns 965 shares of the company’s stock valued at $145,000 after buying an additional 122 shares in the last quarter. First Pacific Financial lifted its holdings in Guardant Health by 33.1% during the 1st quarter. First Pacific Financial now owns 559 shares of the company’s stock worth $52,000 after buying an additional 139 shares during the last quarter. ABS Investment Management LLC acquired a new position in shares of Guardant Health in the 2nd quarter worth approximately $345,069,000. Xponance LLC increased its holdings in shares of Guardant Health by 2.1% in the 4th quarter. Xponance LLC now owns 9,630 shares of the company’s stock valued at $984,000 after acquiring an additional 199 shares during the last quarter. Finally, Danske Bank A S raised its position in shares of Guardant Health by 20.0% during the 4th quarter. Danske Bank A S now owns 1,200 shares of the company’s stock valued at $123,000 after acquiring an additional 200 shares in the last quarter. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on GH. Morgan Stanley raised their target price on shares of Guardant Health from $175.00 to $185.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 4th. UBS Group set a $150.00 price target on Guardant Health in a research note on Wednesday, June 24th. Barclays increased their price target on Guardant Health from $150.00 to $200.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $210.00 price objective on shares of Guardant Health in a research report on Friday, July 31st. Finally, Bank of America lifted their price objective on Guardant Health from $135.00 to $190.00 and gave the company a “buy” rating in a research report on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $183.78.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.